bioRxivCancer BiologyPreprint
Chromosome 7 gain establishes a just-right WNT signaling state during colorectal tumorigenesis
Irene C. ZaalbergiD, Paula C. GasulliD, Martijn J.M. VromansiD, Meritxell Brunet GuaschiD, Natalia Marcekova, Anna VinkeniD, Sjors MiddelkampiD, René WardenaariD, Daniëlle KootiD, Beatriz G. CarvalhoiD, Hugo J.G. SnippertiD, Michael D. NicholsoniD, Floris FoijeriD, Michaël SchubertiD, Susanne M. A. LensiD
Abstract
Aneuploidy is a hallmark of colorectal cancer, yet the functional consequences of recurrent chromosome gains and losses remain largely unknown. Leveraging advances in human colon organoid culture and chromosome copy number engineering, we here identify the gain of chromosome 7 as an adaptive event following APC loss-of-function mutation. Trisomy 7 confers a cell-intrinsic fitness advantage to APC-mutant colon organoids, while selective removal of the additional chromosome 7 copy from patient-derived colon cancer organoids severely impairs colorectal cancer organoid growth. By comparing transcriptomes of isogenic disomy 7 and trisomy 7 organoid lines, we found that chromosome 7 gain promotes organoid fitness through attenuation of excessive WNT-driven stemness caused by bi-allelic APC mutation. The gain of chromosome 7 thus establishes a just-right WNT signaling state. This effect of chromosome 7 gain is conserved from early adenoma-like APC-mutant organoids to advanced colorectal cancer organoids carrying additional oncogenic driver mutations. Moreover, consistent with our organoid data, gain of chromosome 7 is particularly common in tumors of colorectal cancer patients whose APC genotypes confer relatively high WNT activity. Overall, this work demonstrates that chromosome-specific aneuploidy can act as an adaptive mechanism to optimize, rather than maximize, oncogenic signaling during tumor evolution.
- organism: human
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: gene regulatory network inference
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Quantifying "just-right" APC inactivation for colorectal cancer initiation
Meritxell Brunet Guasch, Nathalie A. Feeley, … Tibor Antal A·bioRxiv·Jul 10, 2024
- Beta-catenin mediates growth defects induced by centrosome loss in APC mutant colorectal cancer independently of p53
M. Bourmoum, N. Radulovich, … L. Pelletier·bioRxiv·Feb 13, 2023
- Apc truncation enforces optimal Wnt signalling during early intestinal tumourigenesis
Milou S. van Driel, Nina E. de Groot, … Sanne M. van Neerven·bioRxiv·Feb 12, 2026
- Leveraging WNT Hyperactivation to Kill Colorectal Cancer While Rejuvenating Healthy Intestine.
George M. Eng, Jonathan Braverman, … Ömer H. Yilmaz·bioRxiv·Oct 5, 2025
- USP7 inactivation suppresses APC-mutant intestinal hyperproliferation and tumor development
L. Novellasdemunt, A. Kucharska, … V. S. W. Li·bioRxiv·Sep 22, 2022
- Molecular Drivers of Tumor Progression in Microsatellite Stable APC Mutation-Negative Colorectal Cancers
A. Grant, R. M. Xicola, … M. Padi·bioRxiv·Sep 14, 2021